243 related articles for article (PubMed ID: 9849692)
1. Autologous transplantation of mobilized peripheral blood CD34+ cells selected by immunomagnetic procedures in patients with multiple myeloma.
Abonour R; Scott KM; Kunkel LA; Robertson MJ; Hromas R; Graves V; Lazaridis EN; Cripe L; Gharpure V; Traycoff CM; Mills B; Srour EF; Cornetta K
Bone Marrow Transplant; 1998 Nov; 22(10):957-63. PubMed ID: 9849692
[TBL] [Abstract][Full Text] [Related]
2. Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone.
Alegre A; Tomás JF; Martínez-Chamorro C; Gil-Fernández JJ; Fernández-Villalta MJ; Arranz R; Díaz MA; Granda A; Bernardo MR; Escudero A; López-Lorenzo JL; Fernández-Rañada JM
Bone Marrow Transplant; 1997 Aug; 20(3):211-7. PubMed ID: 9257889
[TBL] [Abstract][Full Text] [Related]
3. CD34+ selection of autologous peripheral blood stem cells for transplantation following sequential cycles of high-dose therapy and mobilization in multiple myeloma.
Dyson PG; Horvath N; Joshua D; Barrow L; Van Holst NG; Brown R; Gibson J; To LB
Bone Marrow Transplant; 2000 Jun; 25(11):1175-84. PubMed ID: 10849530
[TBL] [Abstract][Full Text] [Related]
4. A randomized trial of granulocyte colony-stimulating factor (Neupogen) starting day 1 vs day 7 post-autologous stem cell transplantation.
Bence-Bruckler I; Bredeson C; Atkins H; McDiarmid S; Hamelin L; Hopkins H; Perry G; Genest P; Huebsch L
Bone Marrow Transplant; 1998 Nov; 22(10):965-9. PubMed ID: 9849693
[TBL] [Abstract][Full Text] [Related]
5. Very large amounts of peripheral blood progenitor cells eliminate severe thrombocytopenia after high-dose melphalan in advanced breast cancer patients.
Benedetti G; Patoia L; Giglietti A; Alessio M; Pelicci P; Grignani F
Bone Marrow Transplant; 1999 Nov; 24(9):971-9. PubMed ID: 10556956
[TBL] [Abstract][Full Text] [Related]
6. Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study.
de la Rubia J; Bladé J; Lahuerta JJ; Ribera JM; Martínez R; Alegre A; García-Laraña J; Fernández P; Sureda A; de Arriba F; Carrera D; Besalduch J; García Boyero R; Palomera Bernal L; Hernández MT; García PR; Pérez-Calvo J; Alcalá A; Casado LF; San Miguel J
Haematologica; 2006 May; 91(5):621-7. PubMed ID: 16627253
[TBL] [Abstract][Full Text] [Related]
7. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
8. CD34+ selection of hematopoietic blood cell collections and autotransplantation in lymphoma: overnight storage of cells at 4 degrees C does not affect outcome.
Lazarus HM; Pecora AL; Shea TC; Koç ON; White JM; Gabriel DA; Cooper BW; Gerson SL; Krieger M; Sing AP
Bone Marrow Transplant; 2000 Mar; 25(5):559-66. PubMed ID: 10713636
[TBL] [Abstract][Full Text] [Related]
9. Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+ cells in patients with advanced hematologic malignancies.
Cao TM; Kusnierz-Glaz C; Valone F; Stockerl-Goldstein KE; Hu WW; Johnston L; Blume KG; Strober S; Negrin RS
Cancer; 2001 Jun; 91(12):2205-13. PubMed ID: 11413507
[TBL] [Abstract][Full Text] [Related]
10. Isolation of CD34+ cells from blood stem cell components using the Baxter Isolex system.
Rowley SD; Loken M; Radich J; Kunkle LA; Mills BJ; Gooley T; Holmberg L; McSweeney P; Beach K; MacLeod B; Appelbaum F; Bensinger WI
Bone Marrow Transplant; 1998 Jun; 21(12):1253-62. PubMed ID: 9674860
[TBL] [Abstract][Full Text] [Related]
11. Peripheral blood stem cell transplantation in myeloma using CD34 selected cells.
Johnson RJ; Owen RG; Smith GM; Child JA; Galvin M; Newton LJ; Rawstron A; Major K; Woodhead V; Robinson F; Jack A; Morgan GJ
Bone Marrow Transplant; 1996 May; 17(5):723-7. PubMed ID: 8733688
[TBL] [Abstract][Full Text] [Related]
12. High-dose therapy in multiple myeloma: effect of positive selection of CD34+ peripheral blood stem cells on hematologic engraftment and clinical outcome.
Patriarca F; Damiani D; Fanin R; Grimaz S; Geromin A; Cerno M; Sperotto A; Silvestri F; Zaja F; Baccarani M
Haematologica; 2000 Mar; 85(3):269-74. PubMed ID: 10702815
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of simultaneous immunomagnetic CD34+ cell selection and breast cancer cell purging in peripheral blood progenitor cell samples used for hematopoietic rescue after high-dose therapy.
Mohr M; Hilgenfeld E; Fietz T; Hoppe B; Koenigsmann M; Hoffmann M; Knauf WU; Cassens U; Sibrowski W; Kienast J; Thiel E; Berdel WE
Clin Cancer Res; 1999 May; 5(5):1035-40. PubMed ID: 10353736
[TBL] [Abstract][Full Text] [Related]
14. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
Weaver CH; Schulman KA; Buckner CD
Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
[TBL] [Abstract][Full Text] [Related]
15. Collection of peripheral blood progenitor cells (PBPC) based on a rising WBC and platelet count significantly increases the number of CD34+ cells.
Krieger MS; Schiller G; Berenson JR; Stewart K; Noga SJ; Ballester O; Tarantolo S; Stiff P; Kuhn D; Scherzo E; Sing A; Jacobs C; White JM; DiPersio J
Bone Marrow Transplant; 1999 Jul; 24(1):25-8. PubMed ID: 10435730
[TBL] [Abstract][Full Text] [Related]
16. Isolation and transplantation of highly purified autologous peripheral CD34+ progenitor cells: purging efficacy, hematopoietic reconstitution in non-Hodgkin's lymphoma (NHL): results of Japanese phase II study.
Imai Y; Chou T; Tobinai K; Tanosaki R; Morishima Y; Ogura M; Shimazaki C; Taniwaki M; Hiraoka A; Tanimoto M; Koike T; Kogawa K; Hirai H; Yoshida T; Tamura K; Kishi K; Hotta T;
Bone Marrow Transplant; 2005 Mar; 35(5):479-87. PubMed ID: 15654349
[TBL] [Abstract][Full Text] [Related]
17. CD34(+) hematopoietic progenitor cell selection of bone marrow grafts for autologous transplantation in pediatric patients.
Kasow KA; Sims-Poston L; Eldridge P; Hale GA
Biol Blood Marrow Transplant; 2007 May; 13(5):608-14. PubMed ID: 17448921
[TBL] [Abstract][Full Text] [Related]
18. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
Lemoli RM; Cavo M; Fortuna A
J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
[TBL] [Abstract][Full Text] [Related]
19. Predictors of high yield and purify of CD34(+) cell-selected PBPC, collected from patients with multiple myeloma.
Webb IJ; Scholssman RL; Jiroutek M; Doss D; Cohen CA; Freeman A; Schott DM; Anderson KC
Cytotherapy; 1999; 1(3):175-82. PubMed ID: 12881173
[TBL] [Abstract][Full Text] [Related]
20. Long-term follow-up of patients with non-Hodgkin lymphoma following myeloablative therapy and autologous transplantation of CD34+-selected peripheral blood progenitor cells.
Witzens-Harig M; Heilmann C; Hensel M; Kornacker M; Benner A; Haas R; Fruehauf S; Ho AD
Stem Cells; 2007 Jan; 25(1):228-35. PubMed ID: 17204607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
